A small molecule reduces both parkinsonism and l -dopa–induced dyskinesia in animal models of Parkinson’s disease
Science Translational Medicine · 2026
DOI: 10.1126/scitranslmed.aec7409 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, 2026. Verfasst von Aarash Bordbar und 19 weiteren Autor:innen. Beteiligte Einrichtung: Sinopia Biosciences, San Diego, CA, USA. Hauptthemen laut MEDLINE: Levodopa, Dyskinesia, Drug-Induced, Parkinsonian Disorders, Parkinson Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NINDS NIH HHS, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Maximizing clinical benefits of therapeutics while minimizing adverse effects is a central challenge in drug development. For Parkinson’s disease (PD), l -3,4-dihydroxyphenylalanine ( l -dopa) is the most effective treatment available, but chronic use is associated with periods of reduced efficacy (motor fluctuations) and the debilitating on-target side effect of l -dopa–induced dyskinesia. To disentangle the molecular mechanisms underlying l -dopa’s antiparkinsonian effects versus its dyskinetic effects, we analyzed transcriptomic data from the striata of mice exposed to different l -dopa doses, identifying distinct gene expression signatures associated with l -dopa’s effect on parkinsonian motor symptoms and dyskinesia. By comparing these gene expression signatures with a large dataset of in vitro gene expression profiles of drug perturbations, we identified SB-0107, a positive allosteric modulator of protein kinase A type II with previous clinical experience that boosts l -dopa’s benefits while reducing dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)–lesioned macaque model of PD. Deuterated analogs, including SB-0110, were developed that improved both pharmacokinetics and pharmacological effects. This dual effect, established safety profile of the parent compound, and improved properties of the deuterated analog support further development of this compound as an adjunct treatment to l -dopa therapy for PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Sinopia Biosciences, San Diego, CA, USA.
- Atuka, Toronto, ON, Canada.
- Motac Neuroscience, Bordeaux, France.
- University of Bordeaux, CNRS, Institut des Maladies Neurodégénératives, Bordeaux, France.
- Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, USA.
- Department of Pharmacology, University of California, San Diego, La Jolla, CA, USA.
ORCID-Profile: Aarash Bordbar, Bernard Bloem, Colton Lloyd, Jay S Schneider, Qin Li, Caesar Tawfeeq, Nathan Vu Pham, Gary Huber, Jian Wu, Jonathan M Brotchie, J Andrew McCammon, Friedrich W Herberg, Susan Taylor, David M Weiner, Kalpana Merchant
Förderung
- NIGMS NIH HHS
- NINDS NIH HHS
- National Institute of General Medical Sciences
- National Institute of Neurological Disorders and Stroke
- Michael Fox Foundation for Parkinson Research ID
Zitieren
APA
Bordbar, A., Bloem, B., Lloyd, C., Johnston, T. H., Schneider, J. S., Bezard, E., Pioli, E., Li, Q., Tawfeeq, C., Vu Pham, N., Huber, G., Wu, J., Hill, M. P., Brotchie, J. M., McCammon, J. A., Herberg, F. W., Taylor, S., Weiner, D. M., Merchant, K., & Famili, I. (2026). A small molecule reduces both parkinsonism and l -dopa–induced dyskinesia in animal models of Parkinson’s disease. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aec7409
Vancouver
Bordbar A, Bloem B, Lloyd C, Johnston TH, Schneider JS, Bezard E, et al. A small molecule reduces both parkinsonism and l -dopa–induced dyskinesia in animal models of Parkinson’s disease. Science Translational Medicine. 2026. doi:10.1126/scitranslmed.aec7409
BibTeX
@article{Bordbar2026,
author = {Bordbar, Aarash and Bloem, Bernard and Lloyd, Colton and Johnston, Tom H and Schneider, Jay S and Bezard, Erwan and Pioli, Elsa and Li, Qin and Tawfeeq, Caesar and Vu Pham, Nathan and Huber, Gary and Wu, Jian and Hill, Michael P and Brotchie, Jonathan M and McCammon, J Andrew and Herberg, Friedrich W and Taylor, Susan and Weiner, David M and Merchant, Kalpana and Famili, Iman},
title = {A small molecule reduces both parkinsonism and l -dopa–induced dyskinesia in animal models of Parkinson’s disease},
journal = {Science Translational Medicine},
year = {2026},
doi = {10.1126/scitranslmed.aec7409}
}
EUVIMED